Dyne Therapeutics (DYN) Competitors $10.47 +0.22 (+2.15%) Closing price 04:00 PM EasternExtended Trading$10.46 -0.01 (-0.05%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock DYN vs. ABVX, RNA, MTSR, AKRO, ACLX, ACAD, VKTX, SWTX, SRRK, and PTCTShould you be buying Dyne Therapeutics stock or one of its competitors? The main competitors of Dyne Therapeutics include Abivax (ABVX), Avidity Biosciences (RNA), Metsera (MTSR), Akero Therapeutics (AKRO), Arcellx (ACLX), ACADIA Pharmaceuticals (ACAD), Viking Therapeutics (VKTX), SpringWorks Therapeutics (SWTX), Scholar Rock (SRRK), and PTC Therapeutics (PTCT). These companies are all part of the "pharmaceutical products" industry. Dyne Therapeutics vs. Its Competitors Abivax Avidity Biosciences Metsera Akero Therapeutics Arcellx ACADIA Pharmaceuticals Viking Therapeutics SpringWorks Therapeutics Scholar Rock PTC Therapeutics Abivax (NASDAQ:ABVX) and Dyne Therapeutics (NASDAQ:DYN) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, analyst recommendations, profitability, earnings, risk, institutional ownership, dividends and valuation. Which has more risk and volatility, ABVX or DYN? Abivax has a beta of 0.56, suggesting that its share price is 44% less volatile than the S&P 500. Comparatively, Dyne Therapeutics has a beta of 1.08, suggesting that its share price is 8% more volatile than the S&P 500. Which has better valuation and earnings, ABVX or DYN? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAbivaxN/AN/A-$190.71MN/AN/ADyne TherapeuticsN/AN/A-$317.42M-$3.86-2.71 Do insiders & institutionals believe in ABVX or DYN? 47.9% of Abivax shares are held by institutional investors. Comparatively, 96.7% of Dyne Therapeutics shares are held by institutional investors. 20.8% of Dyne Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Does the media prefer ABVX or DYN? In the previous week, Dyne Therapeutics had 15 more articles in the media than Abivax. MarketBeat recorded 26 mentions for Dyne Therapeutics and 11 mentions for Abivax. Abivax's average media sentiment score of 0.28 beat Dyne Therapeutics' score of 0.28 indicating that Abivax is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Abivax 1 Very Positive mention(s) 1 Positive mention(s) 8 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Dyne Therapeutics 5 Very Positive mention(s) 5 Positive mention(s) 7 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts rate ABVX or DYN? Abivax currently has a consensus price target of $92.33, indicating a potential upside of 30.21%. Dyne Therapeutics has a consensus price target of $36.25, indicating a potential upside of 246.23%. Given Dyne Therapeutics' higher possible upside, analysts clearly believe Dyne Therapeutics is more favorable than Abivax.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Abivax 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13Dyne Therapeutics 0 Sell rating(s) 2 Hold rating(s) 13 Buy rating(s) 2 Strong Buy rating(s) 3.00 Is ABVX or DYN more profitable? Abivax's return on equity of 0.00% beat Dyne Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets AbivaxN/A N/A N/A Dyne Therapeutics N/A -64.12%-56.75% SummaryDyne Therapeutics beats Abivax on 7 of the 12 factors compared between the two stocks. Get Dyne Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DYN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding DYN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DYN vs. The Competition Export to ExcelMetricDyne TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.46B$2.50B$5.55B$9.46BDividend YieldN/A1.78%4.73%4.14%P/E RatioN/A8.9328.9623.99Price / SalesN/A446.79376.3879.74Price / CashN/A22.2824.4827.24Price / Book2.605.068.655.84Net Income-$317.42M$31.61M$3.25B$265.35M7 Day Performance13.80%-1.85%0.45%-1.00%1 Month Performance15.69%5.79%8.27%6.09%1 Year Performance-74.59%5.52%30.29%23.81% Dyne Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DYNDyne Therapeutics3.5873 of 5 stars$10.47+2.1%$36.25+246.2%-74.9%$1.46BN/A0.00100News CoverageUpcoming EarningsABVXAbivax3.6139 of 5 stars$66.57+0.1%$80.00+20.2%+502.1%$4.23BN/A0.0061Upcoming EarningsHigh Trading VolumeRNAAvidity Biosciences2.7011 of 5 stars$34.56-4.7%$66.35+92.0%-9.5%$4.17B$10.90M-11.52190Positive NewsUpcoming EarningsHigh Trading VolumeMTSRMetseraN/A$39.43-2.6%$55.00+39.5%N/A$4.14BN/A0.0081Gap DownAKROAkero Therapeutics4.069 of 5 stars$49.24-2.6%$82.50+67.5%+93.2%$3.93BN/A-25.2530Positive NewsUpcoming EarningsAnalyst ForecastACLXArcellx2.6517 of 5 stars$70.59-1.0%$111.23+57.6%+30.3%$3.89B$107.94M-23.6180News CoveragePositive NewsAnalyst UpgradeACADACADIA Pharmaceuticals3.3958 of 5 stars$22.62-2.7%$28.13+24.3%+28.1%$3.79B$996.28M16.51510Upcoming EarningsVKTXViking Therapeutics3.9289 of 5 stars$33.20-3.5%$86.92+161.8%-35.9%$3.73BN/A-21.7020SWTXSpringWorks Therapeutics0.3755 of 5 stars$46.99flat$52.57+11.9%N/A$3.54B$191.59M-13.78230News CoverageUpcoming EarningsSRRKScholar Rock3.8398 of 5 stars$37.09-4.8%$42.67+15.0%+324.7%$3.52B$33.19M-14.66140Positive NewsUpcoming EarningsPTCTPTC Therapeutics4.4959 of 5 stars$44.36-0.9%$65.77+48.3%+62.3%$3.52B$1.77B6.811,410Upcoming Earnings Related Companies and Tools Related Companies Abivax Competitors Avidity Biosciences Competitors Metsera Competitors Akero Therapeutics Competitors Arcellx Competitors ACADIA Pharmaceuticals Competitors Viking Therapeutics Competitors SpringWorks Therapeutics Competitors Scholar Rock Competitors PTC Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DYN) was last updated on 8/5/2025 by MarketBeat.com Staff From Our PartnersMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredEx-Hedge Fund Manager Uncovers $100 Trillion Land ShiftTrump's Radical New Plan Could Enrich Thousands This isn't a campaign stunt. It's a $100 trillion move to u...Stansberry Research | SponsoredSell these "safe" blue chips immediatelyInvesting Legend Hints the End May be Near for These 3 Iconic Stocks One company to replace Amazon… another...InvestorPlace | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dyne Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Dyne Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
